REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63.
2. Rim CH, Kim CY, Yang DS, Yoon WS. The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies. Cancer Manag Res 2018;10:3305-15.
3. Zeng ZC, Tang ZY, Fan J, et al. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 2005;63:1067-76.
4. Gu X, Li Y, Shi G, et al. Construction of a nomogram model for predicting peritoneal metastasis in gastric cancer: focused on cardiophrenic angle lymph node features. Abdom Radiol (NY) 2023;48:1227-36.
5. Eguchi T, Takasuna K, Nakayama A, Ueda N, Yoshida K, Fujiwara M. Cardiophrenic angle lymph node metastasis from a fallopian primary tumor. Asian Cardiovasc Thorac Ann 2012;20:74-6.
6. Laurent JD, Gockley AA, Cathcart AM, Baranov E, Kolin DL, Worley MJ Jr. Serous borderline tumor of the ovary with isolated cardiophrenic lymph node spread at diagnosis. Gynecol Oncol Rep 2020;33:100586.
7. Holloway BJ, Gore ME, A'Hern RP, Parsons C. The significance of paracardiac lymph node enlargement in ovarian cancer. Clin Radiol 1997;52:692-7.
8. Cho CS, Blank N, Castellino RA. CT evaluation of cardiophrenic angle lymph nodes in patients with malignant lymphoma. AJR Am J Roentgenol 1984;143:719-21.
9. Aronberg DJ, Peterson RR, Glazer HS, Sagel SS. Superior diaphragmatic lymph nodes: CT assessment. J Comput Assist Tomogr 1986;10:937-41.
10. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: hepatocellular carcinoma (version 3.2024). Available from: https://guide.medlive.cn/guideline/32987. [Last accessed on 1 Nov 2024].
11. Zhou J, Sun H, Wang Z, et al. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). Liver Cancer 2023;12:405-44.
12. Zhang H, Chen Y, Hu Y, et al. Image-guided intensity-modulated radiotherapy improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma. Ann Palliat Med 2019;8:717-27.
13. Hu Y, Zhou YK, Chen YX, Shi SM, Zeng ZC. 4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy. Med Phys 2016;43:4335.
14. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
15. Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009;45:261-7.
16. Chen YX, Zeng ZC, Tang ZY, et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010;10:492.
17. Chen YX, Zeng ZC, Fan J, et al. Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases. Clin Transl Oncol 2013;15:732-40.
18. Zhang L, Yan L, Niu H, et al. A nomogram to predict prognosis of patients with unresected hepatocellular carcinoma undergoing radiotherapy: a population-based study. J Cancer 2019;10:4564-73.
19. Tan ZB, Zhang J. Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus. Eur Rev Med Pharmacol Sci 2023;27:8119-34.
20. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol 1998;21:386-91.
21. Cai ZS, Chen MJ, Tang TY, Chang CW. Duodenum perforated after combination with sorafenib and radiotherapy for retroperitoneal lymph node metastasis of hepatocellular carcinoma. J Formos Med Assoc 2020;119:760-2.
22. Kim Y, Park HC, Yoon SM, et al. Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02). Oncotarget 2017;8:94450-61.
23. Hoffe SE, Finkelstein SE, Russell MS, Shridhar R. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control 2010;17:100-10.
24. Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016;34:452-9.
25. Lou J, Li Y, Liang K, et al. Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. BMC Cancer 2019;19:668.
26. Yao E, Chen J, Zhao X, et al. Efficacy of stereotactic body radiotherapy for recurrent or residual hepatocellular carcinoma after transcatheter arterial chemoembolization. Biomed Res Int 2018;2018:5481909.
27. Lai L, Su T, Liang Z, et al. Development and assessment of novel predictive nomograms based on APRI for hepatitis B virus-associated small solitary hepatocellular carcinoma with stereotactic body radiotherapy. J Cancer 2020;11:6642-52.
28. Wee CW, Kim K, Chie EK, Yu SJ, Kim YJ, Yoon JH. Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. Br J Radiol 2016;89:20160383.
29. Tsurugai Y, Takeda A, Eriguchi T, Sanuki N, Aoki Y. Hypofractionated radiotherapy for hepatocellular carcinomas adjacent to the gastrointestinal tract. Hepatol Res 2021;51:294-302.
